A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer

Cancer Immunology, Immunotherapy

Volumn 52, Issue 3, 2003, Pages 155-161

  Iwashita, Yukio ^a   Tahara, Kouichirou ^a   Goto, Shigeru ^a   Sasaki, Atsushi ^a   Kai, Seiichiro ^a   Seike, Masataka ^a   Chen, Chao Long ^b   Kawano, Katsunori ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cell therapy; Cholangiocellular carcinoma; Delayed type hypersensitivity; Hepatocellular carcinoma; Keyhole limpet hemocyanin

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; FEMALE; HUMAN; INOPERABLE CANCER; LIVER CANCER; MALE; PRIORITY JOURNAL; VACCINATION;

EID: 0037384518     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0360-9     Document Type: Article

References (34)

1. Ahrendt SA, Nakeeb A, Pitt HA (2001) Cholangiocarcinoma. Clin Liver Dis 5:191
2. Auffermann-Gretzinger S, Keeffe EB, Levy S (2001) Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97:3171
3. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186:65
4. Brossart P, Bevan MJ (1997) Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90:1594
5. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS (1999) Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59:3134
6. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS (2001) T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 166:5300
7. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T (1996) The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 93:7149
8. Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J (2000) Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 356:1163
9. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ (2001) Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 61:8513
10. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy MS (1994) Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263:518
11. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777
12. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52
13. Kakumu S, Ito S, Ishikawa T, Mira Y, Tagaya T, Fukuzawa Y, Yoshioka K (2000) Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 15:431
14. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332
15. Levin B, Amos C (1995) Therapy of unresectable hepatocellular carcinoma (editorial; comment) [published erratum appears in N Engl J Med 1995;333(10):675]. N Engl J Med 332:1294
16. Liu CL, Fan ST (1997) Nonresectional therapies for hepatocellular carcinoma. Am J Surg 173:358
17. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM (2000) Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191:795
18. Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA (1999) Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 82:121
19. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328
20. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7:23
21. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 7:2277
22. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP (1998) Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35:144
23. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109
24. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A (2001) Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61:6445
25. Schuster MJ, Wu GY (1997) Gene therapy for hepatocellular carcinoma: progress but many stones yet unturned! (editorial; comment). Gastroenterology 112:656
26. Shen Z, Reznikoff G, Dranoff G, Rock KL (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158:2723
27. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG (1999) Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160
28. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271
29. Tahara K, Mori M, Sadanaga N, Sakamoto Y, Kitano S, Makuuchi M (1999) Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 85:1234
30. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower post-surgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802
31. Teo EK, Fock KM (2001) Hepatocellular carcinoma: an Asian perspective. Dig Dis 19:263
32. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 92:11993
33. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS (1999) Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59:3064
34. Zhao X, Wei YQ, Peng ZL (2001) Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest 30:33